DreaMed Advisor

DreaMed Diabetes tool gets FDA approval
By Dave Muoio June 18, 2018
The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes. “This is an innovation that can improve people’s lives and the FDA decision confirms what we believe is an important step in making a more meaningful connection between the healthcare provider and their type 1 diabetes patients...
By Heather Mack July 25, 2016
Israel-based DreaMed Diabetes announced this week that it has raised $3.3 million from Norma Investments, Russian businessman Roman Abramovich and one other unnamed angel. The funds will mainly be used for further development of DreaMed’s Advisor, the company's decision support software that can be licensed and embedded into partners' diabetes management platforms. For example, in February, the...